Omalizumab is effective in symptomatic dermographism—results of a randomized placebo-controlled trial

Symptomatic dermographism (SDerm) is the most common form of physical urticaria with a prevalence of up to 5%.1 SDerm is characterized by itchy wheals that occur in response to friction, for example, after rubbing or scratching of the skin, and usually last for 1 to 2 hours.2 SDerm commonly lasts for years and significantly impairs quality of life (QOL).2 The underlying cause of SDerm is unknown, and the trigger is difficult, if not impossible, to avoid. Therefore, symptomatic treatment with antihistamines is the first-choice treatment.